Vitality Watch

Dossier pubmed review 04-aug-2026
Narrative review or expert overview without new data

How do energy metabolism disorders and neuroinflammation collectively contribute to the pathogenesis of Alzheimer’s disease?

Key claim: Alzheimer’s disease is framed as a systems disorder in which impaired glucose metabolism, mitochondrial dysfunction, and neuroinflammation interact across neurons, astrocytes, and microglia to promote amyloid-β and tau pathology.

Abstract

Alzheimer’s disease (AD), as the leading cause of dementia, poses an increasingly severe socioeconomic burden in the context of global ageing. Traditionally defined by amyloid-β and tau pathology, it’s increasingly recognized as a systems disorder in which impaired glucose metabolism, mitochondrial dysfunction, and neuroinflammation interact across neural cell types and disease stages. However, the interaction among these three mechanisms, their role in promoting the classical pathology of AD, and their verification in major neural cell types remains unclear. This review summarizes the alterations in glucose metabolism and mitochondrial metabolism in neurons, astrocytes and microglia in AD and their relationship with neuroinflammation, while also discussing some unaddressed questions, outlining therapeutic strategies, and future promising directions. Biomarkers that reflect disease stage and pathological status, multitarget therapeutic strategies, individualized precision medicine, and the integration of pharmacological with non-pharmacological interventions represent particularly promising directions for the future.

Why this matters

Alzheimer’s disease is framed as a systems disorder in which impaired glucose metabolism, mitochondrial dysfunction, and neuroinflammation interact across neurons, astrocytes, and microglia to promote amyloid-β and tau pathology.

Source

Link

Briefing card

How do energy metabolism disorders and neuroinflammation collectively contribute to the pathogenesis of Alzheimer's disease?
Stage: review · pubmed · 04-aug-2026

Alzheimer’s disease is framed as a systems disorder in which impaired glucose metabolism, mitochondrial dysfunction, and neuroinflammation interact across neurons, astrocytes, and microglia to promote amyloid-β and tau pathology.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: doi:10.1016/j.arr.2026.103287

build build 880 · 2bcef25 · 2026-11-18